The Efficacy and Safety of Valsartan in Obese and Non-Obese Pediatric Hypertensive Patients
| Autor: | Susan Solar-Yohay, Victor Shi, Guangyang Han, Kenneth Lieberman, Kevin E.C. Meyers |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
business.industry Endocrinology Diabetes and Metabolism medicine.disease Placebo Comorbidity Surgery law.invention Dose–response relationship Randomized controlled trial Valsartan Tolerability law Internal medicine Post-hoc analysis Internal Medicine medicine Cardiology and Cardiovascular Medicine Adverse effect business medicine.drug |
| Zdroj: | The Journal of Clinical Hypertension. 13:758-766 |
| ISSN: | 1524-6175 |
| Popis: | J Clin Hypertens (Greenwich). 2011;13:758–766. ©2011 Wiley Periodicals, Inc. This post hoc analysis assessed the efficacy and tolerability of valsartan for the treatment of hypertension in obese vs non-obese children and adolescents. After a 1-week antihypertensive washout period, 142 obese and 119 non-obese hypertensive children and adolescents aged 6 to 16 years were randomized to 2 weeks of once-daily treatment with valsartan 10 to 20 mg, 40 to 80 mg, or 80 to 160 mg, followed by re-randomization to either valsartan or placebo for an additional 2 weeks. Patients could continue to receive valsartan during an optional 52-week, open-label extension. Valsartan resulted in statistically significant (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|